Wei et al. demonstrated that sorafenib, a multi-kinase inhibitor employed in hepatocarcinoma and in relapsed FLT3-ITD acute myeloid leukemia, not only inhibits ABCG2 efflux activity but induces ABCG2 degradation in the lysosome [169]. The gene discussed is ABCG2; the disease is acute myeloid leukemia.